Atorvastatin Calcium Trihydrate

證據等級: L5

預測適應症: 0 個

Atorvastatin Calcium Trihydrate: Drug Repurposing Evaluation (No Predictions Available in Current Evidence Pack)

One-Sentence Summary

Atorvastatin Calcium Trihydrate is a well-established statin, originally used to treat hypercholesterolaemia and to reduce cardiovascular risk by inhibiting HMG-CoA reductase. The current Evidence Pack contains no TxGNN predicted indications for this drug, meaning repurposing modelling output is not yet available for evaluation. Until prediction data is generated, it is not possible to assess evidence strength or assign a recommendation.

Quick Overview

Item	Content
Original Indication	Hypercholesterolaemia / Cardiovascular risk reduction (statin class; confirmed from drug class knowledge — formal NPRA indication text not retrieved)
Predicted New Indication	— Not available (predicted_indications is empty)
TxGNN Prediction Score	— Not available
Evidence Level	L5 (model prediction data absent; no supporting studies assessable at this time)
Malaysia Market Status	✓ Marketed
Number of Registrations	32
Recommended Decision	Hold

Why Is a Prediction Reasonable?

At this stage, no repurposing target has been generated by the TxGNN model for this drug, so no mechanistic link to a new indication can be formally evaluated.

For reference, Atorvastatin belongs to the statin class and acts as a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway. Beyond lipid lowering, statins exhibit pleiotropic effects — including anti-inflammatory, immunomodulatory, and anti-proliferative properties — that have motivated repurposing hypotheses across multiple disease areas (e.g., Alzheimer’s disease, multiple sclerosis, certain cancers). However, none of these directions can be formally scored or ranked without the TxGNN prediction output.

Detailed mechanism of action data is also recorded as a data gap (DG002) in the current pack. Once DrugBank data is retrieved and the TxGNN prediction pipeline is run, this section will be populated with ranked candidate indications.

Clinical Trial Evidence

Currently no related clinical trials registered — prediction target not yet defined; section will be populated once TxGNN output is available.

Literature Evidence

Currently no related literature available — prediction target not yet defined; section will be populated once TxGNN output is available.

Malaysia Market Information

The drug holds 32 registrations with the NPRA (Malaysia) and is confirmed as marketed. However, the individual licence records retrieved in this Evidence Pack contain no populated fields (licence number, product name, dosage form, approved indication text are all blank). The table below reflects the current state of the data:

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	—

Note: Licence-level detail (product names, dosage forms, approved indications) must be retrieved from the NPRA portal to complete this section. 32 registrations confirm a well-established market presence consistent with Atorvastatin being a first-line cardiovascular medication.

Safety Considerations

Please refer to the package insert for safety information.

Safety data gaps have been logged for this candidate:

DG001 (Blocking): NPRA/TFDA package insert warnings and contraindications have not been retrieved. This blocks the S1 safety pre-screen step. Remediation: download and parse the package insert PDF from the official source.

No drug–drug interaction records were returned in this evidence pack (query status: not found).

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction pipeline has not yet produced output for Atorvastatin Calcium Trihydrate, making it impossible to identify, score, or evaluate any repurposing candidate indication. Without a target indication, none of the downstream evaluation steps (mechanistic plausibility, clinical trial evidence, literature evidence, safety profiling) can be completed.

To proceed, the following is needed:

Run TxGNN prediction — execute the KG + DL prediction pipeline with Atorvastatin’s DrugBank ID to generate ranked candidate indications
Retrieve DrugBank ID — the drugbank_id field is null; map “ATORVASTATIN CALCIUM TRIHYDRATE” to its canonical DrugBank entry (DB01076) to enable model input (Data Gap DG002)
Retrieve MOA data — query DrugBank API to populate mechanism of action (Data Gap DG002)
Retrieve NPRA package insert details — download and parse the approved indication text, warnings, and contraindications for the 32 registered products (Data Gap DG001; severity: Blocking)
Populate licence-level data — ensure the 32 NPRA registration records include product name, dosage form, and approved indication text
Re-run evidence collection — once a predicted indication is available, collect ClinicalTrials.gov, PubMed, and ICTRP evidence for that specific drug–disease pair
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.